Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Physiol ; 591(9): 2333-44, 2013 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-23459759

RESUMEN

Ageing is associated with a decline in muscle mass and strength leading to increased physical dependency in old age. Postmenopausal women experience a greater decline than men of similar age in parallel with the decrease in female sex steroid hormone production. We recruited six monozygous female twin pairs (55-59 years old) where only one twin pair was on hormone replacement therapy (HRT use = 7.8 ± 4.3 years) to investigate the association of HRT with the cytoplasmic volume supported by individual myonuclei (myonuclear domain (MND) size,) together with specific force at the single fibre level. HRT use was associated with a significantly smaller (∼27%; P < 0.05) mean MND size in muscle fibres expressing the type I but not the IIa myosin heavy chain (MyHC) isoform. In comparison to non-users, higher specific force was recorded in HRT users both in muscle fibres expressing type I (∼27%; P < 0.05) and type IIa (∼23%; P < 0.05) MyHC isoforms. These differences were fibre-type dependent, i.e. the higher specific force in fast-twitch muscle fibres was primarily caused by higher force per cross-bridge while slow-twitch fibres relied on both a higher number and force per cross-bridge. HRT use had no effect on fibre cross-sectional area (CSA), velocity of unloaded shortening (V0) and relative proportion of MyHC isoforms. In conclusion, HRT appears to have significant positive effects on both regulation of muscle contraction and myonuclei organization in postmenopausal women.


Asunto(s)
Estradiol/farmacología , Terapia de Reemplazo de Hormonas , Fibras Musculares Esqueléticas/efectos de los fármacos , Progesterona/farmacología , Gemelos Monocigóticos , Anciano , Anciano de 80 o más Años , Composición Corporal , Núcleo Celular , Femenino , Humanos , Masculino , Persona de Mediana Edad , Contracción Muscular/efectos de los fármacos , Fibras Musculares Esqueléticas/citología , Fibras Musculares Esqueléticas/fisiología , Cadenas Pesadas de Miosina/metabolismo , Posmenopausia , Isoformas de Proteínas/metabolismo
2.
Muscle Nerve ; 44(5): 769-75, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22006692

RESUMEN

INTRODUCTION: Postmenopausal monozygotic twin pairs discordant for hormone replacement therapy (HRT) provide an advantageous study design controlling for genetic background for elucidating the relationships between aging, sex hormone levels, muscle strength, contractile capacity, and fatigability. METHODS: Thirteen postmenopausal monozygotic twin pairs discordant for HRT were measured for maximal voluntary torque (MVC) and twitch characteristics using electrical stimulation before and after intermittent dynamic plantarflexor exercise until exhaustion. RESULTS: Peak twitch torque was 32% higher in HRT users than in their non-HRT, genetically identical sisters (P = 0.002), but MVC did not differ. There were no differences in the activation level or twitch time characteristics between the co-twins. Fatigue caused decreases in MVC (P = 0.001), twitch torque (P = 0.001), time to peak (P = 0.013), and half-relaxation time (P = 0.001) similarly in HRT users and non-HRT users. CONCLUSION: In early postmenopausal women, involuntary but not voluntary force-generating mechanisms of the plantarflexors are augmented by the use of HRT.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Contracción Muscular/fisiología , Fatiga Muscular/fisiología , Músculo Esquelético/fisiología , Gemelos Monocigóticos , Electromiografía/métodos , Estradiol/sangre , Estradiol/uso terapéutico , Terapia de Reemplazo de Estrógeno/métodos , Femenino , Humanos , Persona de Mediana Edad , Contracción Muscular/efectos de los fármacos , Fatiga Muscular/efectos de los fármacos , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Músculo Esquelético/efectos de los fármacos , Gemelos Monocigóticos/genética
3.
J Appl Physiol (1985) ; 107(1): 25-33, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19246654

RESUMEN

We investigated whether long-term hormone replacement therapy (HRT) is associated with mobility and lower limb muscle performance and composition in postmenopausal women. Fifteen 54- to 62-yr-old monozygotic female twin pairs discordant for HRT were recruited from the Finnish Twin Cohort. Habitual (HWS) and maximal (MWS) walking speeds over 10 m, thigh muscle composition, lower body muscle power assessed as vertical jumping height, and maximal isometric hand grip and knee extension strengths were measured. Intrapair differences (IPD%) with 95% confidence intervals (CI) were calculated. The mean duration of HRT use was 6.9 +/- 4.1 yr. MWS was on average 7% (0.9 to 13.1%, P = 0.019) and muscle power 16% (-0.8 to 32.8%, P = 0.023) greater in HRT users than in their cotwins. Thigh muscle cross-sectional area tended to be larger (IPD% = 6%, 95% CI: -0.07 to 12.1%, P = 0.065), relative muscle area greater (IPD% = 8%, CI: 0.8 to 15.0%, P = 0.047), and relative fat area smaller (IPD% = -5%, CI: -11.3 to 1.2%, P = 0.047) in HRT users than in their sisters. There were no significant differences in maximal isometric strengths or HWS between users and nonusers. Subgroup analyses revealed that estrogen-containing therapies (11 pairs) significantly decreased total body and thigh fat content, whereas tibolone (4 pairs) tended to increase muscle cross-sectional area. This study showed that long-term HRT was associated with better mobility, greater muscle power, and favorable body and muscle composition among 54- to 62-yr-old women. The results indicate that HRT is a potential agent in preventing muscle weakness and mobility limitation in older women.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Estrógenos/farmacología , Menopausia/fisiología , Contracción Muscular/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Estrógenos/sangre , Femenino , Fuerza de la Mano/fisiología , Humanos , Contracción Isométrica/fisiología , Persona de Mediana Edad , Contracción Muscular/fisiología , Músculo Esquelético/diagnóstico por imagen , Músculo Esquelético/fisiología , Tomografía Computarizada por Rayos X , Estudios en Gemelos como Asunto , Gemelos Monocigóticos , Caminata/fisiología
4.
Cell Microbiol ; 10(3): 667-81, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18042259

RESUMEN

Baculovirus, Autographa californica multiple nucleopolyhedrovirus (AcMNPV), has the ability to transduce mammalian cell lines without replication. The general objective of this study was to detect the transcription and expression of viral immediate-early genes in human cells and to examine the interactions between viral components and subnuclear structures. Viral capsids were seen in large, discrete foci in nuclei of both dividing and non-dividing human cells. Concurrently, the transcription of viral immediate-early transregulator genes (ie-1, ie-2) and translation of IE-2 protein were detected. Quantitative microscopy imaging and analysis showed that virus transduction altered the size of promyelocytic leukaemia nuclear bodies, which are suggested to be involved in replication and transcription of various viruses. Furthermore, altered distribution of the chromatin marker Draq5 and histone core protein (H2B) in transduced cells indicated that the virus was able to induce remodelling of the host cell chromatin. To conclude, this study shows that the non-replicative insect virus, baculovirus and its proteins can induce multiple changes in the cellular machinery of human cells.


Asunto(s)
Expresión Génica , Genes Inmediatos-Precoces , Nucleopoliedrovirus/genética , Proteínas Virales/biosíntesis , Animales , Antraquinonas/metabolismo , Cápside/metabolismo , Línea Celular , Núcleo Celular/química , Núcleo Celular/virología , Ensamble y Desensamble de Cromatina , Histonas/metabolismo , Humanos , Ratones , Microscopía Confocal , Microscopía Fluorescente
5.
Twin Res Hum Genet ; 12(1): 108-17, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19210186

RESUMEN

The physically active lifestyle is associated with low future morbidity and mortality, but the causality between physical activity and health is not always clear. As some inherited biological characteristics and childhood experiences may cause selection bias in observational studies, we sought to take them into account by identifying 16 twin pairs (7 MZ, 9 DZ, mean age 60 years) discordant for leisure time physical activity habits for thirty years. We conducted detailed health-related examinations among these twin pairs. Our main aims were to study the effects of physical activity and genes on fitness and body composition, with special reference to body fat compartments, metabolic syndrome components and related diseases and risk factor levels, status of arteries, structure and function of the heart, bone properties, and muscle and fat tissue-related mechanisms linked to physical activity and chronic disease development. Our physical activity assessments showed that inactive co-twins were on average 8.8 MET hours/day less active than their active co-twins through out their midlife (2.2+/-2.3 vs. 11.0+/-4.1 MET h/day, p< .001). Follow-up fitness tests showed that physically inactive co-twins were less fit than their active co-twins (estimated VO(2peak) 26.4+/-4.9 vs. 32.5+/-5.5 ml/kg/min, p< .001). Similar differences were found in both MZ and DZ pairs. On the basis of earlier epidemiological observations on nonrelated individuals, these physical activity and fitness differences are large enough to cause differences in many mechanisms and risk factors related to the development of chronic diseases and to permit future analyses.


Asunto(s)
Tejido Adiposo , Síndrome Metabólico/genética , Aptitud Física , Gemelos Dicigóticos/genética , Gemelos Monocigóticos/genética , Adolescente , Adulto , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
6.
Rejuvenation Res ; 10(4): 485-500, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17985945

RESUMEN

The loss of muscle mass and strength with aging is well characterized, but our knowledge of the molecular mechanisms underlying the development of sarcopenia remains incomplete. Although menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood. Furthermore the knowledge of the global transcriptional changes that take place in skeletal muscle in relation to estrogen status has thus far been completely lacking. We used a randomized double-blinded study design together with an explorative microarray experiment to characterize possible effects of continuous, combined HRT and estrogen deprivation on the skeletal muscle of fifteen women. Here, we report the differential response of both Gene Ontology-annotated biological processes and some individual genes responding differentially to the use or non-use of HRT. Our results revealed transcription level changes in, for example, muscle protein and energy metabolism. In particular, the ubiquitine-proteosome system was found to be effected at several levels. HRT seemed to partially counteract the postmenopause-related transcriptional changes. Our results suggest that during the early postmenopausal years, when there is no counteracting medication available, muscle transcriptome changes notably, whereas HRT appears to slow down this phenomenon and could therefore aid in maintaining proper muscle mass and function after menopause.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Perfilación de la Expresión Génica , Músculo Esquelético/metabolismo , Posmenopausia/metabolismo , Femenino , Regulación de la Expresión Génica , Humanos , Persona de Mediana Edad , Análisis de Secuencia por Matrices de Oligonucleótidos , ARN Mensajero/análisis , Receptores de Estrógenos/genética
7.
Menopause ; 19(12): 1329-35, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22914204

RESUMEN

OBJECTIVE: The aim of this study was to evaluate the possibility of preventing the metabolic health consequences of postmenopausal hypogonadism with the use of long-term hormone therapy (HT). METHODS: We used a monozygotic co-twin control design including 10 twin pairs (aged 56-62 y) discordant for HT (duration of HT, 2-10 y). In addition, 14 premenopausal women (aged 29-35 y) who did not use HT were studied to evaluate the differences in metabolic health between the premenopausal and postmenopausal states. Body composition was determined, and waist-to-hip ratio was used as an estimate for fat distribution. Serum sex steroids, sex hormone-binding globulin, and serum lipid and glucose profiles were analyzed. The serum levels of adiponectin, monocyte chemotactic protein-1, and leptin, as well as their local transcript levels in adipose tissue, skeletal muscle, and leukocytes, were measured. RESULTS: Long-term HT was associated with a healthier amount and distribution of body fat. No difference was seen in serum lipid concentrations between HT users and their nonusing identical twin sisters, but fasting serum glucose and glycated hemoglobin levels were 5% and 3% lower in HT users than in nonusers, respectively. Among the adipokines analyzed, the most notable finding was a 15% lower level of monocyte chemotactic protein-1 in HT users, particularly with respect to its suggested mediator role between obesity and insulin resistance. CONCLUSIONS: Long-term HT is associated with healthier amount and distribution of body fat and better adipocytokine profile, with concomitant signs of improved insulin sensitivity.


Asunto(s)
Adipoquinas/sangre , Glucemia/análisis , Composición Corporal , Terapia de Reemplazo de Estrógeno , Posmenopausia/fisiología , Adipoquinas/genética , Tejido Adiposo/química , Adulto , Estudios de Casos y Controles , Quimiocina CCL2/sangre , Femenino , Hormonas Esteroides Gonadales/sangre , Humanos , Resistencia a la Insulina , Leucocitos/química , Lípidos/sangre , Persona de Mediana Edad , Músculo Esquelético/química , Premenopausia , ARN Mensajero/análisis , Globulina de Unión a Hormona Sexual/análisis , Gemelos Monocigóticos , Relación Cintura-Cadera
8.
Age (Dordr) ; 34(5): 1249-60, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21845403

RESUMEN

A thorough understanding of the role of estrogens on aging-related muscle weakness is lacking. To clarify the molecular mechanisms underlying the effects of hormone replacement therapy (HRT) on skeletal muscle, we analyzed systemic protein and local mRNA levels of factors related to interleukin 6 (IL-6) and insulin-like growth factor 1 (IGF-1) pathways in 30- to 35-year-old (n = 14) women (without hormonal contraceptives) and in 54- to 62-year-old monozygotic female twin pairs discordant for HRT (n = 11 pairs, mean duration of HRT 7.3 ± 3.7 years). Biopsies were taken from vastus lateralis muscle and from abdominal adipose tissue. We found, first, that the systemic levels of IL-6 receptors sIL-6R and sgp130 are sensitive to both age and HRT concomitant with the changes in body composition. The serum levels of sgp130 and sIL-6R were 16% and 52% (p ≤ 0.001 for both variables) higher in postmenopausal women than in premenopausal women, and 10% and 9% lower (p = 0.033 and p < 0.001, respectively) in the HRT using than in their non using co-twins. After adjustment for body fat amount, the differences were no more significant. Second, the transcript analyses emphasize the impact of adipose tissue on systemic levels of IL-6, sgp130 and sIL6R, both at pre- and postmenopausal age. In muscle, the most notable changes were 28% lower gene expression of IGF-1 splice variant Ea (IGF-1Ea) and 40% lower expression of splice variant Ec (IGF-1Ec) in the postmenopausal non-users than in premenopausal women (p = 0.016 and 0.019, respectively), and 28% higher expression of IGF1-receptor in HRT users than in non-users (p = 0.060). The results tend to demonstrate that HRT has positive anti-catabolic effect on aging skeletal muscle.


Asunto(s)
Tejido Adiposo/metabolismo , Envejecimiento/genética , Terapia de Reemplazo de Estrógeno , Expresión Génica , Interleucina-6/genética , Músculo Esquelético/metabolismo , ARN/genética , Adulto , Femenino , Humanos , Interleucina-6/metabolismo , Leucocitos/metabolismo , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , ARN/biosíntesis , Receptor IGF Tipo 1/metabolismo
9.
Aging Cell ; 10(4): 650-60, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21388496

RESUMEN

Aging is associated with gradual decline of skeletal muscle strength and mass often leading to diminished muscle quality. This phenomenon is known as sarcopenia and affects about 30% of the over 60-year-old population. Androgens act as anabolic agents regulating muscle mass and improving muscle performance. The role of female sex steroids as well as the ability of skeletal muscle tissue to locally produce sex steroids has been less extensively studied. We show that despite the extensive systemic deficit of sex steroid hormones in postmenopausal compared to premenopausal women, the hormone content of skeletal muscle does not follow the same trend. In contrast to the systemic levels, muscle tissue of post- and premenopausal women had similar concentrations of dehydroepiandrosterone and androstenedione, while the concentrations of estradiol and testosterone were significantly higher in muscle of the postmenopausal women. The presence of steroidogenetic enzymes in muscle tissue indicates that the elevated postmenopausal steroid levels in skeletal muscle are because of local steroidogenesis. The circulating sex steroids were associated with better muscle quality while the muscle concentrations reflected the amount of infiltrated fat within muscle tissue. We conclude that systemically delivered and peripherally produced sex steroids have distinct roles in the regulation of neuromuscular characteristics during aging.


Asunto(s)
Envejecimiento/fisiología , Hormonas Esteroides Gonadales/metabolismo , Músculo Esquelético/fisiología , Adulto , Anciano , Androstenodiona/metabolismo , Androstenodiona/farmacología , Antropometría , Estudios de Cohortes , Deshidroepiandrosterona/metabolismo , Deshidroepiandrosterona/farmacología , Femenino , Expresión Génica , Hormonas Esteroides Gonadales/farmacología , Humanos , Persona de Mediana Edad , Músculo Esquelético/anatomía & histología , Músculo Esquelético/efectos de los fármacos , Posmenopausia , Premenopausia
10.
J Bone Miner Res ; 26(3): 546-52, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20878773

RESUMEN

Although postmenopausal hormone-replacement therapy (HRT) is known to prevent fractures, knowledge on the influence of long-term HRT on bone strength and its determinants other than areal bone mineral density is scarce. This study used a genetically controlled design with 24 monozygotic female twin pairs aged 54 to 72 years in which one cotwin was using HRT (mean duration 8 years) and the other had never used HRT. Estimated bone strength, cross-sectional area, volumetric bone mineral density, bone mineral mass, and cross-sectional density and mass distributions were assessed in the tibial shaft, distal tibia, and distal radius with peripheral computed tomography (pQCT). In the tibial shaft, HRT users had 9% [95% confidence interval (CI) 3%-15%] higher estimated bending strength than their nonusing cotwins. Larger cortical area and higher cortical bone mineral density accounted for this difference. The cortex was larger in the HRT users in the endocortical region. In the distal tibia, estimated compressive strength was 24% (95% CI 9%-40%) higher and in the distal radius 26% (95% CI 11%-41%) higher in the HRT users than in their nonusing cotwins owing to higher volumetric bone mineral density. No difference between users and nonusers was observed in total bone cross-sectional area in any measured bone site. The added mineral mass in the HRT users was distributed evenly within and between bone sites. In postmenopausal women, long-term HRT preserves estimated bone strength systemically by preventing bone mineral loss similarly in body weight-loaded and non-weight-loaded bone.


Asunto(s)
Huesos/anatomía & histología , Huesos/fisiología , Terapia de Reemplazo de Estrógeno , Gemelos Monocigóticos , Anciano , Antropometría , Composición Corporal , Densidad Ósea/fisiología , Diáfisis/patología , Diáfisis/fisiología , Femenino , Hormonas/sangre , Humanos , Persona de Mediana Edad , Tamaño de los Órganos , Autoinforme , Factores de Tiempo , Gemelos Monocigóticos/sangre
11.
Growth Horm IGF Res ; 20(5): 372-9, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20724185

RESUMEN

OBJECTIVES: To investigate the effects of combined hormone replacement therapy (HRT) and its effective agents on the IGF-1 signaling pathway. DESIGN AND METHODS: To examine the effects of HRT on skeletal muscle in vivo, we utilized pre- and post-intervention samples from a randomized double blinded trial with 50-57-year-old women. The intervention included the year-long use of either HRT preparation (2 mg 17ß-estradiol, E2; 1mg norethisterone acetate, NETA, n=10) or placebo (CO, n=9). Microarray technology and quantitative PCR (qPCR) were used to study the expression of insulin-like growth factor I (IGF-1) and its splice variants as well as IGF-1 receptor, Akt1, mTOR, FOXO1, FOXO3, atrogin, estrogen receptors and androgen receptor in muscle samples. Serum concentrations of IGF-1, E(2) and testosterone were measured. C2C12 myotubes were fed with E2 or NETA followed by analyzing the expression of essentially the same gene transcripts as in human samples by qPCR and phosphorylation of Akt and mTOR by Western blotting. RESULTS: The gene expression of IGF-1 and its splice variant, IGF-1Ec (also known as the mechano growth factor or MGF), mTOR, FOXO3, and AR was up-regulated among the HRT users compared to the CO (P<0.05), while Akt1 was down-regulated (P<0.05). The change in the level of IGF-1Ec transcript correlated positively with muscle size at post-intervention (r=0.5, P<0.05). In C2C12 myotubes, no statistically significant effects of either E2 or NETA at the level of gene transcripts studied were identified. The amount of phosphorylated Akt appeared to respond to NETA, albeit the response was not statistically significant. Phosphorylation of mTOR did not respond to either of the treatments. CONCLUSION: Year-long postmenopausal HRT was found to affect the expression of the genes along the IGF-1 signaling cascade reflecting the higher muscle mass compared to the CO women. By using cell culture model we were, however, unable to confirm the possible differential role of E2 and NETA. It appears that the synchronous presence of both effective agents of the HRT or the presence of yet unidentified microenvironmental factors providing proper paracrine signals naturally existing in the intact muscle tissue is critical for appropriate signaling via sex steroid-IGF-1 axis to occur.


Asunto(s)
Estradiol/uso terapéutico , Terapia de Reemplazo de Estrógeno , Factor I del Crecimiento Similar a la Insulina/biosíntesis , Músculo Esquelético/efectos de los fármacos , Noretindrona/análogos & derivados , Estradiol/sangre , Femenino , Proteína Forkhead Box O1 , Proteína Forkhead Box O3 , Factores de Transcripción Forkhead/biosíntesis , Factores de Transcripción Forkhead/genética , Humanos , Factor I del Crecimiento Similar a la Insulina/análisis , Factor I del Crecimiento Similar a la Insulina/genética , Persona de Mediana Edad , Fibras Musculares Esqueléticas/química , Fibras Musculares Esqueléticas/efectos de los fármacos , Proteínas Musculares/biosíntesis , Proteínas Musculares/genética , Músculo Esquelético/química , Noretindrona/uso terapéutico , Acetato de Noretindrona , Isoformas de Proteínas/biosíntesis , Isoformas de Proteínas/genética , Proteínas Proto-Oncogénicas c-akt/biosíntesis , Proteínas Proto-Oncogénicas c-akt/genética , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptor IGF Tipo 1/biosíntesis , Receptor IGF Tipo 1/genética , Receptores Androgénicos/biosíntesis , Receptores Androgénicos/genética , Receptores de Estrógenos/biosíntesis , Receptores de Estrógenos/genética , Proteínas Ligasas SKP Cullina F-box/biosíntesis , Proteínas Ligasas SKP Cullina F-box/genética , Serina-Treonina Quinasas TOR/biosíntesis , Serina-Treonina Quinasas TOR/genética , Testosterona/sangre , Transcripción Genética/efectos de los fármacos
12.
Aging Cell ; 9(6): 1098-110, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20883525

RESUMEN

Aging is accompanied by inexorable loss of muscle tissue. One of the underlying causes for this is the massive change in the hormonal milieu of the body. The role of a female sex steroid - estrogen - in these processes is frequently neglected, although the rapid decline in its production coincides with a steep deterioration in muscle performance. We recruited 54- to 62-year-old monozygotic female twin pairs discordant for postmenopausal hormone replacement therapy (HRT, n=11 pairs; HRT use 7.3 ± 3.7 years) from the Finnish Twin Cohort to investigate the association of long-term, estrogen-based HRT with skeletal muscle transcriptome. Pathway analysis of muscle transcript profiles revealed significant HRT-induced up-regulation of a biological process related to regulation of cell structure and down-regulation of processes concerning, for example, cell-matrix interactions, energy metabolism and utilization of nutrients (false discovery rate < 0.15). Lending clinical relevance to the findings, these processes explained a significant fraction of the differences observed in relative proportion of muscle within thigh and in muscle performance (R(2) =0.180-0.257, P=0.001-0.023). Although energy metabolism was affected through down-regulation of the transcripts related to succinate dehydrogenase complex in mitochondria, no differences were observed in mtDNA copy number or oxidative capacity per muscle cross section. In conclusion, long-term use of HRT was associated with subtle, but significant, differences in muscle transcript profiles. The better muscle composition and performance among the HRT users appeared to be orchestrated by improved regulatory actions on cytoskeleton, preservation of muscle quality via regulation of intramuscular extracellular matrix and a switch from glucose-oriented metabolism to utilization of fatty acids.


Asunto(s)
Terapia de Reemplazo de Estrógeno/métodos , Perfilación de la Expresión Génica , Músculo Esquelético/metabolismo , Gemelos Monocigóticos/genética , Estudios de Cohortes , Variaciones en el Número de Copia de ADN , ADN Mitocondrial/genética , Regulación hacia Abajo , Femenino , Humanos , Persona de Mediana Edad , Succinato Deshidrogenasa/genética
13.
Age (Dordr) ; 32(3): 347-63, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20640546

RESUMEN

At the moment, there is no clear molecular explanation for the steeper decline in muscle performance after menopause or the mechanisms of counteractive treatments. The goal of this genome-wide study was to identify the genes and gene clusters through which power training (PT) comprising jumping activities or estrogen containing hormone replacement therapy (HRT) may affect skeletal muscle properties after menopause. We used musculus vastus lateralis samples from early stage postmenopausal (50-57 years old) women participating in a yearlong randomized double-blind placebo-controlled trial with PT and HRT interventions. Using microarray platform with over 24,000 probes, we identified 665 differentially expressed genes. The hierarchical clustering method was used to assort the genes. Additionally, enrichment analysis of gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was carried out to clarify whether assorted gene clusters are enriched with particular functional categories. The analysis revealed transcriptional regulation of 49 GO/KEGG categories. PT upregulated transcription in "response to contraction"-category revealing novel candidate genes for contraction-related regulation of muscle function while HRT upregulated gene expression related to functionality of mitochondria. Moreover, several functional categories tightly related to muscle energy metabolism, development, and function were affected regardless of the treatment. Our results emphasize that during the early stages of the postmenopause, muscle properties are under transcriptional modulation, which both PT and HRT partially counteract leading to preservation of muscle power and potentially reducing the risk for aging-related muscle weakness. More specifically, PT and HRT may function through improving energy metabolism, response to contraction as well as by preserving functionality of the mitochondria.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Músculo Esquelético/metabolismo , Posmenopausia , Transcripción Genética/efectos de los fármacos , Ejercicio Físico , Femenino , Humanos , Persona de Mediana Edad , Músculo Esquelético/efectos de los fármacos
14.
PLoS One ; 3(3): e1819, 2008 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-18350156

RESUMEN

BACKGROUND: Muscle strength declines on average by one percent annually from midlife on. In postmenopausal women this decrement coincides with a rapid decline in estrogen production. The genetics underlying the effects of estrogen on skeletal muscle remains unclear. In the present study, we examined whether polymorphisms within COMT and ESR1 are associated with muscle properties and assessed their interaction and their combined effects with physical activity. METHODOLOGY/PRINCIPAL FINDINGS: A cross-sectional data analysis was conducted with 434 63-76-year-old women from the population-based Finnish Twin Study on Aging. Body anthropometry, muscle cross-sectional area (mCSA), isometric hand grip and knee extension strengths, and leg extension power were measured. COMT Val158Met and ESR1 PvuII genotypes were determined by the RFLP method. mCSA differed by COMT genotypes (p = 0.014) being significantly larger in LL than HL individuals in unadjusted (p = 0.001) and age- and height-adjusted model (p = 0.004). When physical activity and age were entered into GEE model, COMT genotype had a significant main effect (p = 0.038) on mCSA. Furthermore, sedentary individuals with the HH genotype had lower muscle mass, strength and power, but they also appeared to benefit the most from physical activity. No association of ESR1 PvuII polymorphism with any of the muscle outcomes was observed. CONCLUSIONS/SIGNIFICANCE: The present study suggests that the COMT polymorphism, affecting the activity of the enzyme, is associated with muscle mass. Furthermore, sedentary individuals with potential high enzyme activity were the weakest group, but they may potentially benefit the most from physical activity. This observation elucidates the importance of both environmental and genetic factors in muscle properties.


Asunto(s)
Catecol O-Metiltransferasa/genética , Ejercicio Físico , Músculo Esquelético/fisiología , Polimorfismo Genético , Anciano , Femenino , Humanos , Persona de Mediana Edad , Músculo Esquelético/enzimología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA